Covid 19 Research using Clinical Trials (Home Page)
LEAF-4L7520Wiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
|
Name (Synonyms) |
Correlation |
drug1308 | LEAF-4L6715 Wiki | 1.00 |
drug222 | Assessing antibody responses, neutralizing capacity and memory B-cell function Wiki | 1.00 |
Correlated MeSH Terms (4)
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
This is an open label phase II study of treatment with LEAF-4L7520 and LEAF-4L6715 in
patients who experience severe acute respiratory distress syndrome (ARDS) and are receiving
artificial respiratory support due to COVID-19. The purpose of this study is to evaluate the
improvement in PaO2/FiO2 by more than 25% in two cohorts of patients treated with LEAF-4L7520
or LEAF-4L6715.
Primary Outcomes
Measure: proportion of patients showing an increase of at least 25% of PaO2/FiO2 ratio Time: 24 hours
Secondary Outcomes
Measure: proportion of patients with a PaO2/FiO2 ratio above 200 mm Hg Time: 24, 48 and 72 hours
Measure: all cause mortality Time: 28 days
No related HPO nodes (Using clinical trials)